Published Paper Details:

Background: Ischemia-modified albumin (IMA) is a novel biomarker of ischemia and oxidative stress. Several studies have demonstrated elevated IMA levels in diabetes mellitus (DM). Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia, dyslipidemia, and increased oxidative stress, predisposing patients to cardiovascular complications. The present study aimed to estimate serum IMA levels in patients with T2DM and evaluate its correlation with glycemic status and lipid profile parameters. Materials and Methods: A total of 200 subjects were recruited from the Medicine Outpatient Department of INDEX Medical College and Hospital. Among them, 100 patients were diagnosed with T2DM according to ADA 2016 guidelines, and 100 age- and sex-matched healthy individuals served as controls. Fasting blood sugar (FBS), postprandial blood sugar (PPBS), HbA1c, lipid profile, malondialdehyde (MDA), reduced glutathione (GSH), and serum IMA were measured. Statistical analysis was performed using Student's t-test and Pearson's correlation test. Results: Patients with T2DM exhibited significantly higher levels of FBS, PPBS, HbA1c, total cholesterol, triglycerides, LDL-cholesterol, MDA, and IMA, along with significantly lower HDL-cholesterol and GSH levels compared to controls (p < 0.05). Serum IMA showed a significant positive correlation with FBS, PPBS, HbA1c, total cholesterol, triglycerides, and LDL-cholesterol, while a negative correlation was observed with HDL-cholesterol. Conclusion: Serum IMA levels are significantly elevated in patients with T2DM and are strongly associated with poor glycemic control and dyslipidemia. IMA may serve as an early biomarker for ischemia and cardiovascular risk in patients with type 2 diabetes mellitus, aiding in better disease management and prognosis.